Distinct evolution of SARS-CoV-2 Omicron XBB and BA. 2.86/JN. 1 lineages combining increased fitness and antibody evasion

D Planas, I Staropoli, V Michel, F Lemoine… - Nature …, 2024 - nature.com
The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral
sublineages. Here, we isolate and characterize XBB. 1, XBB. 1.5, XBB. 1.9. 1, XBB. 1.16. 1 …

From De Novo Design to Redesign: Harnessing Computational Protein Design for Understanding SARS-CoV-2 Molecular Mechanisms and Developing Therapeutics

AK Padhi, P Kalita, S Maurya, KM Poluri… - The Journal of …, 2023 - ACS Publications
The continuous emergence of novel SARS-CoV-2 variants and subvariants serves as
compelling evidence that COVID-19 is an ongoing concern. The swift, well-coordinated …

Neutralization against Omicron subvariants after BA. 5/BF. 7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based …

H Wang, Q Xue, H Zhang, G Yuan, X Wang… - Emerging Microbes & …, 2023 - Taylor & Francis
Background: Omicron had swept the mainland China between December 2022 and January
2023, while SARS-CoV-2 still continued to evolve. To fully prepare for the next wave, it's …

Repeated Omicron exposures redirect SARS-CoV-2–specific memory B cell evolution toward the latest variants

R Kotaki, S Moriyama, S Oishi, T Onodera… - Science Translational …, 2024 - science.org
Immunological imprinting by ancestral SARS-CoV-2 strains is thought to impede the robust
induction of Omicron-specific humoral responses by Omicron-based booster vaccines. Here …

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

T Inoue, Y Yamamoto, K Sato, Y Okemoto-Nakamura… - Iscience, 2024 - cell.com
A current challenge is the emergence of SARS-CoV-2 variants, such as BQ. 1.1 and XBB.
1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness …

Understanding the Molecular Actions of Spike Glycoprotein in SARS-CoV-2 and Issues of a Novel Therapeutic Strategy for the COVID-19 Vaccine

Y Matsuzaka, R Yashiro - BioMedInformatics, 2024 - mdpi.com
In vaccine development, many use the spike protein (S protein), which has multiple “spike-
like” structures protruding from the spherical structure of the coronavirus, as an antigen …

Locuaz: an in silico platform for protein binders optimization

GP Barletta, R Tandiana, M Soler, S Fortuna… - …, 2024 - academic.oup.com
Motivation Engineering high-affinity binders targeting specific antigenic determinants
remains a challenging and often daunting task, requiring extensive experimental screening …